AXSM - Axsome Therapeutics Inc logo

Axsome Therapeutics Inc

AXSM
Rev โ€”top 1%10Y
Compare AXSM Hold

Axsome Therapeutics develops therapies for central nervous system disorders, focusing on conditions like major depressive disorder, excessive daytime sleepiness, and migraines. Its key products include Auvelity, Sunosi, and Symbravo, generating revenue from these treatments.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$24,543today

Score Overview

1 Year
Score
Net Growth-4.62%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth21.62%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.4
Net Growth-42.02%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth88x
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-5x
Net Trend10%
Net Income Consistency
Rev Growthโ€”
Rev Trend60%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-13x
Net Trend9%
Net Income Consistency
Rev Growthโ€”
Rev Trend55%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Axsome Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AXSM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 193.89โ€”
1 Year2025-09-26
$ 116.7666.06%
5 Years2021-09-28
$ 33.23483.48%
10 Years2016-09-28
$ 7.9024x
All Time2015-11-19
$ 8.7422x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 776M-$ 191M$ 319M
2025$ 638M-$ 183M$ 322M
2024$ 385M-$ 287M$ 315M
2023$ 270M-$ 239M$ 386M
2022$ 50M-$ 187M$ 200M
2021$ 8M-$ 134M$ 86M
2020$ 0.00-$ 102M$ 183M
2019$ 0.00-$ 68M$ 219M
2018$ 0.00-$ 30M$ 13M
2017$ 0.00-$ 28M$ 34M
2016$ 0.00-$ 27M$ 36M
IPO2015$ 0.00-$ 12M$ 48M
AXSM - Axsome Therapeutics Inc logo

Axsome Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 0.00 to $ 638M and net income went from -$ 102M to -$ 183M. Revenue increased in every one of those 5 years; net income in 1.

Axsome Therapeutics Inc currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.

Membership

Explore AXSM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies